Elzaki Wail M, Abubakr Neamat H, Ziada Hassan M, Ibrahim Yahia E
Department of Oral Rehabilitation, Faculty of Dentistry, University of Khartoum, Khartoum, Sudan; Faculty of Dentistry, King Khalid University, South Region/Abha, Kingdom of Saudi Arabia.
Department of Clinical Dental Science, College of Dentistry, Princess Nourah Bint Abdulrahman University, Riyadh, Kingdom of Saudi Arabia.
J Endod. 2016 Jun;42(6):835-42. doi: 10.1016/j.joen.2016.02.014. Epub 2016 Apr 12.
The present clinical trial aimed to evaluate the efficiency of paracetamol alone and in combination with 3 different nonsteroidal anti-inflammatory drugs for control of post-endodontic pain.
The inclusion criteria were moderate to severe pain of irreversible pulpitis, by using the Verbal Rating Scale and a 4-10 score on the Numerical Rating Scale, on anterior or premolar teeth, as well as the absence of signs and symptoms of apical periodontitis. One hundred eighty-five trial medications with placebo were prepared, and 170 participants completed the trial. There were 5 groups. P-group received 4 gelatinous capsules of a single dose of paracetamol alone. The IP-group received similar capsules of a single dose of combined ibuprofen/paracetamol. MP-group received combined mefenamic acid/paracetamol, and DP-group received combined diclofenac K/paracetamol. A Plb-group received doubled gelatinous capsules with no medications as a single dose, which had the same weight and appearance as the medicated capsules, to be the placebo.
Pain intensity was measured after initial endodontic therapy and instrumentation by using the Verbal Rating Scale and Numerical Rating Scale. IP-group (ibuprofen/paracetamol) had the most pain reduction, followed by DP-group (combined diclofenac K/paracetamol), then MP-group, followed by P-group, whereas Plb-group had the least pain reduction (P < .05).
The combination of ibuprofen/paracetamol, taken immediately after initial endodontic therapy and root canal preparation in teeth with irreversible pulpitis, reduced post-endodontic pain (ClinicalTrials.gov no.: NCT02417337).
本临床试验旨在评估对乙酰氨基酚单独使用以及与3种不同非甾体抗炎药联合使用对控制根管治疗后疼痛的效果。
纳入标准为前牙或前磨牙出现中度至重度不可逆性牙髓炎疼痛,采用语言评定量表(Verbal Rating Scale)和数字评定量表(Numerical Rating Scale)评分为4 - 10分,且无根尖周炎的体征和症状。制备了185份含安慰剂的试验药物,170名参与者完成了试验。分为5组。P组单独服用4粒单剂量对乙酰氨基酚凝胶胶囊。IP组服用类似的单剂量布洛芬/对乙酰氨基酚联合胶囊。MP组服用甲芬那酸/对乙酰氨基酚联合胶囊,DP组服用双氯芬酸钾/对乙酰氨基酚联合胶囊。Plb组服用双倍重量且外观与含药胶囊相同但无药物的凝胶胶囊作为单剂量安慰剂。
在首次根管治疗和器械操作后,使用语言评定量表和数字评定量表测量疼痛强度。IP组(布洛芬/对乙酰氨基酚)疼痛减轻最多,其次是DP组(双氯芬酸钾/对乙酰氨基酚联合),然后是MP组,接着是P组,而Plb组疼痛减轻最少(P < 0.05)。
对于患有不可逆性牙髓炎的牙齿,在首次根管治疗和根管预备后立即服用布洛芬/对乙酰氨基酚组合药物,可减轻根管治疗后疼痛(临床试验注册号:NCT02417337)。